UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Lumvoa has been on the U.S. market since its FDA approval on June 26, 2026, with first doses in July and $981.5 million of cash and securities at June 30. UnitedHealthcare’s new coverage criteria took effect on October 1, a subcutaneous rival faces an FDA decision due by October 15, and the elegrobart BLA is guided for the first quarter of 2027.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
All three windows come from the second-quarter release of August 6, 2026, and none is a fixed date. A check of SEC filings and company releases through October 4, 2026 found no new dated Viridian event: the last company release was the September 2 notice of the Wells Fargo conference presentation scheduled for September 8, and the third-quarter results date had not been announced.
On June 29, 2026 Genentech said the FDA had granted Priority Review to its supplemental application for Enspryng (satralizumab), an at-home subcutaneous injection, in TED, with a decision expected by October 15, 2026. In SatraGO-2, 53% of treated patients reached a proptosis response at week 24 versus 23% on placebo; in SatraGO-1 the figures were 49% versus 31% and the difference was not statistically significant. An approval would bring an at-home subcutaneous option to market well before elegrobart, whose BLA is guided for Q1 2027. It is not a Viridian event, and a target date is not a decision.
Approved product, first patient doses in July, 95% of 2,000 core prescribers engaged by July 31, a broad TED indication and $981.5 million of cash and securities at June 30 provide a commercial platform. A European filing is under review and Japan is partnered. Elegrobart could extend the franchise if approved.
Paid uptake is not yet quantified: Q2 revenue was $0.284 million of license and collaboration revenue, with no product sales. UnitedHealthcare reviews Lumvoa under its launch program and caps it at five lifetime doses, and a subcutaneous rival faces an FDA decision due by October 15. Hearing warnings, launch spending and royalty sharing remain. The funding outlook assumes future sales.
June 30, 2026 cash, equivalents and marketable securities totaled $981.530 million. First-half operations used $224.978 million, before Lumvoa’s first July doses. The $75 million DRI receivable was collected in July and is separate from June cash. Management’s funding-through-break-even statement assumes future Lumvoa and elegrobart revenue; it is not a cash-only runway guarantee. The launch and Q1 2027 elegrobart filing plan must therefore be assessed alongside access, paid uptake, spending and financing obligations. June 30 Form 10-Q
Lumvoa’s June approval gives Viridian a commercial product and a five-infusion treatment course, but the July launch has not yet established recurring paid demand. Insurer criteria and competition separate an approved label from accessible treatment. Elegrobart offers a subcutaneous development path, supported by positive primary endpoints, while some diplopia outcomes differed by regimen and study. June liquidity and July DRI receipts provide resources, with debt, royalties and possible dilution remaining relevant. The central question is whether launch execution and later regulatory progress can convert clinical differentiation into durable revenue at an acceptable cost. Neither physician engagement nor a large historical cash balance answers that question alone.
New criteria cap Lumvoa at five lifetime doses, Tepezza at eight, and exclude patients already treated with the other drug. Lumvoa has been on the Review at Launch list since July 15.
Schedule 13G with an August 19 event date. In August, Paradigm (6.1%), Kynam (5.7%), State Street (5.5%) and T. Rowe Price (5.2%) also reported holdings as of June 30.
Q2 reporting confirms launch progress. June cash excludes a $75M DRI receivable collected in July; $40M of REVEAL milestones are no longer available.
Genentech’s subcutaneous Enspryng in TED has an FDA decision expected by October 15, 2026. SatraGO-2 hit its proptosis endpoint; SatraGO-1 did not reach significance.
How robust or fragile the company looks over the next twelve to eighteen months, scored 1 to 5 across five weighted pillars. Assessed on October 4, 2026.
| Balance sheet and runway · 30% | 4.0 / 5 | $981.5M of cash and securities at June 30, 2026 plus the $75M DRI receivable collected in July; Hercules debt repaid. The break-even funding statement depends on future Lumvoa and elegrobart revenue. |
| Catalysts · 30% | 3.5 / 5 | Lumvoa approved and launched; elegrobart BLA guided for Q1 2027, EMA review of veligrotug pending. No dated company catalyst; the next dated event is a competitor decision due by October 15. |
| Dilution · 20% | 3.0 / 5 | 12.1M shares issuable from preferred stock and about 10.1M from the 2032 convertible notes at the initial rate, after an 8.46M-share equity sale in May 2026. |
| Liquidity · 10% | 4.0 / 5 | Float of 106.36M shares and a Russell 2000 listing; short interest of 19.47M shares at the September 15, 2026 settlement date, about 18.3% of float, can amplify moves in both directions. |
| Execution · 10% | 3.5 / 5 | Approval came before the PDUFA date and the launch started at once, but the REVEAL-linked DRI milestones of $40M were missed and paid uptake is not yet reported. |
This is not an indication to buy or sell. It is a description of financial and operational robustness, not a rating, a target price or a recommendation, and it says nothing about whether the shares are worth their price.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
The bull case is stronger after the June 26 approval because Viridian now owns an approved TED product. The label covers TED regardless of activity or duration, and the five-infusion, 12-week course is a simple differentiation message. If physicians respond to the active/chronic data and payers allow reasonable access, Lumvoa can build revenue faster than a development-stage model assumed.
Elegrobart is the larger strategic opportunity. After positive REVEAL-1 and REVEAL-2 data, Viridian targets a BLA in Q1 2027; if approved, an at-home subcutaneous option could expand the treated population among patients who would not pursue IV infusions, growing the category rather than only taking share from Tepezza.
The balance sheet supports the transition: $981.5 million of cash and securities at June 30, high-cost Hercules debt repaid, WuXi commercial supply in place, a European application under review and Japan partnered with Kissei. Confidence may improve if the first launch indicators show real prescription momentum with disciplined spending.
The bear case now begins with commercial adoption, not FDA approval. Lumvoa can underperform if physicians stay with Tepezza, if payers manage access tightly, if infusion logistics slow patient starts, or if its differentiation proves useful but not enough to drive share gains.
Safety perception is another red flag. The label warns of infusion reactions, inflammatory bowel disease, hyperglycemia and hearing impairment that may be severe and in some cases permanent, and the pooled adverse-event profile, detailed in section 06, will shape physician and patient conversations.
Elegrobart could also remain commercially debated. Payers and physicians will compare efficacy, safety, durability, cost and label details, and subcutaneous Tepezza and Enspryng could narrow its convenience advantage.
Access and competition have become concrete. UnitedHealthcare has reviewed Lumvoa under its launch program since July 15, 2026 and, since October 1, limits it to five lifetime doses, and Genentech’s at-home subcutaneous Enspryng has an FDA decision expected by October 15. Q2 net loss was $127.119 million and first-half operating cash outflow $224.978 million. Management’s funding-through-profitability outlook includes anticipated future Lumvoa and, if approved, elegrobart revenue; it is not a cash-only guarantee.
A gradual launch would require repeated evidence of paid treatment starts, coverage decisions, course completion and revenue quality. Early physician contact does not establish those outcomes.
Elegrobart remains investigational with a Q1 2027 filing target. A shared commercial infrastructure could help execution if approved, while pricing, safety, competition and capital consumption remain separate risks.
Lumvoa provides an approved but commercially unproven platform, supported by historical cash resources and an investigational follow-on product. The following observations would test material assumptions, with their timing and context considered together.
These are conditional tests of the assessment, not predictions of clinical results, regulatory decisions or share-price reactions.
October 1, 2026 close $18.99 (Marketstack). Finviz, as of October 2: float 106.36M. Short interest was 19,465,251 shares at the September 15, 2026 settlement date (FINRA data published by Nasdaq), about 18.3% of that float; days-to-cover figures differ by volume base and are therefore not shown. These are dated measurements, not forecasts.
Common shares 113.238M plus preferred conversion 12.111M equals 125.349M at June 30; the 10-Q cover reported 113,292,269 common shares on August 3. Finviz institutional ownership 119.37% and insider 6.12% are not mutually exclusive buckets; an ownership pie would be misleading.
Millions of shares at June 30. Total 125.349092M before notes/options.
Source: Viridian · SEC Q2 2026
The June 26, 2026 approval came ahead of the June 30 PDUFA target action date, and the company stated that physicians could prescribe Lumvoa the day after the announcement.
Lumvoa is indicated for TED regardless of disease activity or duration. The company highlights that the product is the first approved TED treatment with labeling that includes data for both active and chronic disease, and the first approved TED product to show a statistically significant effect in both diplopia response and complete resolution of diplopia in active and chronic TED.
ViridianCares™, activated at approval, offers patient access liaisons, insurance coverage support, benefit verification and financial assistance for eligible patients, which matters because TED biologic adoption depends on reimbursement navigation, infusion logistics and affordability as much as on medical demand.
The June 29 approval webcast and the Wells Fargo healthcare conference presentation scheduled for September 8, 2026 are both historical. As of October 4, 2026 Viridian had not announced the date of its third-quarter results.
The May 24, 2026 agreement with WuXi Biologics for long-term commercial supply of veligrotug drug substance and drug product, described in section 15, is now part of the operational backbone of the launch.
Viridian submitted a Marketing Authorization Application for veligrotug to the European Medicines Agency in January 2026, according to the Q2 2026 Form 10-Q; no EU decision date has been disclosed. In Japan, a July 2025 agreement gives Kissei Pharmaceutical exclusive rights to develop and commercialize veligrotug and elegrobart, with a $70.0 million upfront payment, up to $315.0 million of further milestones and tiered royalties from the twenties to the mid-thirties percent of Japanese net sales.
The FDA novel drug approvals list records Lumvoa / veligrotug-vvze with an approval date of June 26, 2026 and the approved use “to treat thyroid eye disease”; the prescribing information specifies TED regardless of disease activity or duration.
The label supports a simple commercial message: five IV infusions over 12 weeks. The recommended dosage is 10 mg/kg administered by intravenous infusion every three weeks for a total of five infusions. Lumvoa is not given as an IV push or bolus and should not be infused concomitantly with other agents. The first infusion is administered over 45 minutes. If the first infusion is well tolerated, subsequent infusions can be administered over a minimum of 30 minutes; if not well tolerated, subsequent infusions should remain at a minimum of 45 minutes.
Lumvoa is supplied as a 500 mg/10 mL single-dose vial containing 50 mg/mL of veligrotug-vvze. The diluted infusion solution is prepared in a 250 mL 0.9% sodium chloride infusion bag. The label states that the diluted solution can be stored for four hours at room temperature or up to 72 hours under refrigerated conditions, protected from light, and should be allowed to reach room temperature before administration if refrigerated.
The label lists no contraindications. Infusion reactions occurred in approximately 9% of Lumvoa-treated patients and may include transient blood pressure increases, fever, chills, headache and fatigue. The label instructs clinicians to interrupt or slow the infusion and use appropriate medical management if an infusion reaction occurs.
The inflammatory bowel disease warning is also important because IGF-1R class therapies have been associated with IBD exacerbation. The label says Lumvoa may cause exacerbation of IBD and instructs clinicians to monitor patients for signs and symptoms, including patients without a prior IBD history. If IBD is suspected, Lumvoa should be discontinued.
Hyperglycemia is a clear monitoring issue. The prescribing information says hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of patients experienced hyperglycemia, and about half of those patients had pre-existing diabetes or impaired glucose tolerance. Patients should be assessed for elevated blood glucose and symptoms before infusion and monitored during treatment, with continued monitoring after treatment for patients who experience hyperglycemia while receiving Lumvoa.
Hearing impairment remains one of the biggest safety perception issues for the franchise. The label warns that Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. It instructs clinicians to assess hearing before, during and after treatment and to consider the benefit-risk of treatment with patients, which makes it a counseling and adoption variable as well as a medical caveat.
The pooled clinical-trial safety table gives investors a concrete adverse-event profile. In Study 1 and Study 2 combined, 200 patients received Lumvoa and 101 received placebo. Adverse reactions at 5% or more and greater than placebo included muscle spasms 40% versus 7%, headache 17% versus 14%, hearing impairment 15% versus 6%, hyperglycemia 13% versus 5%, fatigue 13% versus 11%, diarrhea 11% versus 7%, ear discomfort 10% versus 3%, infusion-related reaction 9% versus 2%, nausea 8% versus 6%, nasopharyngitis 7% versus 1%, blood creatine phosphokinase increased 6% versus 1%, dry skin 6% versus 2%, and hypertension 6% versus 5%.
The reproductive-risk language also belongs in the hub. Because IGF-1R signaling has a role in embryonic and placental development, Lumvoa may cause fetal harm. The label says Lumvoa should not be used during pregnancy and that females of reproductive potential should use effective contraception before initiation, during treatment and for six months after the last dose. Pediatric safety and effectiveness have not been established.
The pooled adverse-reaction table reports hearing impairment 15% versus 6% placebo and hyperglycemia 13% versus 5%. The warning section uses 12% for its hyperglycemia description; categories differ. Placebo-adjusted percentages are not total event rates, and separate trials are not direct treatment comparisons.
Approved labelViridian is a biotechnology company focused on medicines for autoimmune and rare diseases, built on antibody discovery and protein engineering against validated targets. Its public-market value is concentrated in TED, but the platform is broader than one antibody.
The TED strategy is built around IGF-1R inhibition: Lumvoa is the approved intravenous product, and elegrobart is the subcutaneous follow-on designed for lower-volume, potentially at-home autoinjector use. A Lumvoa launch can create the field force, payer relationships, patient support and distribution experience that could later support elegrobart with limited incremental investment, if it is approved.
Viridian is also developing an anti-TSHR program for TED and Graves’ disease and an FcRn inhibitor portfolio that includes VRDN-006 and VRDN-008. They are not the primary 2026 value driver: if TED works commercially, investors may give more credit to the platform; if it fails, earlier-stage programs are unlikely to offset the damage in the near term.
Thyroid eye disease is an autoimmune condition frequently associated with Graves’ disease. It can cause inflammation, swelling and tissue remodeling around and behind the eye. Clinically, patients can experience proptosis, pain, pressure, redness, eyelid swelling, double vision, altered appearance and functional impairment. The disease has an active inflammatory phase and a chronic or more stable phase. That distinction matters because treatment needs, trial populations and commercial behavior can differ substantially between active and chronic disease.
Chronic TED patients may live with persistent proptosis or diplopia for years after inflammation stabilizes, often managed through observation or surgery. A therapy that works convincingly in chronic disease supports a broader market, but it still has to be effective, safe, reimbursable and convenient enough to bring those patients back into care.
Tepezza validated TED as a commercial biologic category and set the benchmark. Viridian’s pitch is a lighter IV burden with five infusions over 12 weeks now, and a subcutaneous option later if elegrobart is approved.
| Program | Mechanism / format | Status | Key upcoming milestone | Stock relevance |
|---|---|---|---|---|
| Lumvoa / veligrotug-vvze | Intravenous anti-IGF-1R monoclonal antibody | FDA approved on June 26, 2026 for treatment of TED regardless of disease activity or duration; MAA submitted to the EMA in January 2026; Japan rights licensed to Kissei | Immediate U.S. launch, first commercial execution readouts, payer access updates and early revenue signals | Main approved product and first test of Viridian’s commercial TED strategy |
| Elegrobart | Subcutaneous, half-life-extended anti-IGF-1R antibody designed for autoinjector use | Positive phase 3 topline data in REVEAL-1 active TED and REVEAL-2 chronic TED | BLA submission anticipated in Q1 2027 | Potential second-wave asset and key reason VRDN is broader than one approved IV product |
| Anti-TSHR program | Half-life-extended monoclonal antibody inhibiting thyroid-stimulating hormone receptor | Preclinical / IND-enabling | IND expected in Q4 2026 | Longer-term TED/Graves’ optionality |
| VRDN-006 | Fc fragment FcRn inhibitor | Phase 1 proof-of-concept IgG reduction reported in healthy volunteers | Development plan expected in 2026 | Autoimmune platform optionality, but not the core 2026 driver |
| VRDN-008 | Half-life-extended bispecific FcRn inhibitor | IND accepted in January 2026; phase 1 healthy volunteer study ongoing | Phase 1 healthy volunteer data expected in 2H 2026 | Important early pipeline asset; valuation credit depends first on TED launch execution |
January 2021 — Viridian identity takes shape
Viridian Therapeutics emerged from the former Miragen Therapeutics identity and increasingly repositioned around antibody-based therapies for serious and rare diseases.
October 2023 — Steve Mahoney becomes CEO
Steve Mahoney became President and Chief Executive Officer and joined the board, bringing rare-disease commercial, operating, legal and financial experience from Magenta, Kiniksa, Synageva and Genzyme-related work.
September 2024 — THRIVE active TED data
Veligrotug met all primary and secondary endpoints in active TED.
December 2024 — THRIVE-2 chronic TED data
Veligrotug met all primary and secondary endpoints in chronic TED.
May 2025 — Breakthrough Therapy Designation
Veligrotug received FDA Breakthrough Therapy Designation.
October 2025 — BLA submission and financing architecture
Viridian submitted the veligrotug BLA and strengthened the balance sheet through equity, royalty and credit structures, including the DRI royalty financing and amended Hercules facility.
December 2025 / January 2026 — FDA Priority Review
The FDA accepted the veligrotug BLA under Priority Review with a June 30, 2026 PDUFA target action date.
March 30, 2026 — REVEAL-1 active TED
Elegrobart met the primary endpoint in active TED, and the stock subsequently declined. Competitive expectations are one possible interpretation, not a demonstrated cause.
May 5, 2026 — REVEAL-2 chronic TED
Elegrobart delivered positive chronic TED data, with 50% and 54% PRR versus 15% placebo and statistically significant Q4W diplopia response, following the March decline; market reactions do not establish clinical superiority.
May 6–11, 2026 — Financing reset
Viridian priced and closed concurrent offerings of convertible notes and common stock, with $350.0 million aggregate gross proceeds announced and $250.0 million aggregate principal amount of notes after the over-allotment exercise.
May 24–27, 2026 — Supply and debt cleanup
Viridian entered a commercial manufacturing services agreement with WuXi Biologics for veligrotug supply, then prepaid approximately $55.1 million to retire its Hercules term loan.
June 2–3, 2026 — Annual meeting results
Stockholders elected directors and approved the other governance proposals.
June 26, 2026 — FDA approval and launch announcement
The FDA approved Lumvoa for the treatment of TED regardless of disease activity or duration. Viridian announced an immediate U.S. launch, making Lumvoa the company’s first approved medicine and first commercial product.
June 29, 2026 — Approval conference call
Management discussed the Lumvoa approval and launch plan.
August 6, 2026 — Second-quarter results
First Lumvoa doses in July, 95% of 2,000 core prescribers engaged by July 31, and $981.5 million of cash and securities at June 30.
October 1, 2026 — UnitedHealthcare policy in force
The insurer’s revised Lumvoa and Tepezza policy sets coverage criteria, including a five-dose lifetime cap. Lumvoa had been on its Review at Launch list since July 15, 2026.
Q1 2027 — Elegrobart BLA target
The next large regulatory setup is the anticipated U.S. BLA submission for subcutaneous elegrobart, which could become the convenience-driven follow-on product if approved.
The product’s approved position is clear. Lumvoa is an IV anti-IGF-1R antibody indicated for the treatment of TED regardless of disease activity or duration. The regimen is 10 mg/kg every three weeks for five infusions, giving Viridian a 12-week treatment-course message. That shorter course is central to the launch story.
The pivotal package includes THRIVE in active TED and THRIVE-2 in chronic TED. The active-study topline release reported 70% week-15 proptosis response versus 5% placebo and complete diplopia resolution of 54% versus 12%. The approved label instead reports 49% versus 12% for diplopia resolution using its stated analysis; the historical topline and label values are not interchangeable. The topline release reported no treatment-related serious adverse events and a 5.5-percentage-point placebo-adjusted hearing-impairment difference.
For chronic TED, the topline release reported 56% week-15 proptosis response versus 8% placebo; the approved label reports 57% versus 8%. Diplopia response was 56% versus 25%, and complete resolution 32% versus 14%. The topline release reported 94% treatment completion and a 9.6-percentage-point placebo-adjusted hearing-impairment difference. The label’s analysis and warnings provide the current regulatory reference; historical releases preserve the original reported results.
The next proof points are prescription behavior, payer access quality, patient-start conversion, infusion-center logistics, gross-to-net discipline and the first reported product revenue.
UnitedHealthcare’s revised commercial policy for Lumvoa and Tepezza took effect on October 1, 2026. Lumvoa remains in the insurer’s Review at Launch program, to which it was added on July 15, 2026 and under which some members may not yet be eligible for coverage; the new policy sets criteria for those who are: moderate-to-severe TED, a prescriber who is an endocrinologist or ophthalmologist, no prior treatment with the other drug, and a cap of five lifetime Lumvoa doses against eight for Tepezza. The latest company announcement Merlintrader has found is the September 2 conference notice. The next dated event in the TED market is a competitor’s: the FDA decision on Genentech’s subcutaneous Enspryng, expected by October 15.
Elegrobart is the subcutaneous candidate that could make Viridian’s TED story much larger than a single IV PDUFA. It is designed as a half-life-extended anti-IGF-1R antibody with the same binding domain as veligrotug, and the company has positioned it as a potential first subcutaneous autoinjector treatment for TED.
REVEAL-1 met its primary Q4W proptosis endpoint: 54% versus 18% placebo at week 24; Q8W reported 63%. Q4W diplopia response was 71% versus 32% and resolution 51% versus 16%, but these downstream tests were nominal because the prespecified hierarchy stopped at CAS 0/1 (57% versus 50%, p=0.24). They are not confirmatory secondary successes. The subsequent share decline is observed; disappointed competitive expectations are a possible interpretation, not an established cause. Placebo-adjusted hearing-impairment differences were 11.3 and 2.3 percentage points for Q4W and Q8W, respectively, not absolute event rates.
REVEAL-2 randomized 204 chronic TED patients 1:1:1. Week-24 proptosis response was 50% Q4W and 54% Q8W versus 15% placebo, both p<0.0001. Diplopia response was 61% versus 38% for Q4W (p=0.0118); Q8W was 55% versus 38% (p=0.0419), which did not meet the stated 0.025 threshold. Complete resolution was 44% Q4W and 36% Q8W versus 25%; neither met that threshold (p=0.0295 and 0.1304). Placebo-adjusted hearing-impairment differences were 4.1 and 8.8 percentage points for Q4W and Q8W, not absolute rates. The company reported no treatment-related serious adverse events.
Elegrobart now has positive phase 3 evidence in both active and chronic TED, which gives Viridian a more complete portfolio. Because Lumvoa is already approved and launched, its commercial and medical affairs infrastructure can potentially support elegrobart later; the company said on August 6 that it expects this with limited incremental investment. A BLA submission, expected in Q1 2027, is not approval, and approval is not adoption.
The March 2026 selloff is essential to the VRDN story. REVEAL-1 met its primary endpoint, so the trial reduced development risk; it did not eliminate commercial risk. Investors were asking whether elegrobart could look clearly superior in a market already anchored by Tepezza.
Positive primary proptosis results did not prevent a share decline. REVEAL-1 Q4W diplopia findings were nominal after the hierarchy failed at CAS. Competitive expectations may help explain the reaction, but the price movement does not establish investor motives or clinical superiority.
Viridian closed Q2 2026 with a substantial cash position. As of June 30, 2026, the company reported $981.5 million in cash, cash equivalents and marketable securities, up from $762.2 million at March 31 and $874.7 million at December 31, 2025, with the May financing the reason the balance rose while the company was losing money. Q2 2026 net loss was $127.1 million, compared with $100.7 million in Q2 2025. Research and development expense fell to $71.6 million from $86.6 million a year earlier, as veligrotug and elegrobart study costs came down. Selling, general and administrative expense rose to $55.0 million from $20.2 million, the cost of building the commercial infrastructure for the Lumvoa launch.
The May 2026 financing is best understood in context. On May 6, Viridian announced the pricing of concurrent offerings: $225.0 million aggregate principal amount of 1.75% convertible senior notes due 2032 and 7,352,942 common shares at $17.00 per share. The announced aggregate gross proceeds were $350.0 million, and estimated net proceeds were approximately $334.7 million. Underwriters also received options to buy up to an additional $25.0 million principal amount of notes and up to 1,102,941 common shares. The note over-allotment was exercised, bringing the May 11 closing to $250.0 million aggregate principal amount of notes plus the common stock sale.
The company said the net proceeds would be used to repay Hercules indebtedness, fund market expansion studies for the TED franchise, advance earlier pipeline research and development, and support working capital and general corporate purposes. On May 27, Viridian prepaid approximately $55.1 million to retire all outstanding obligations under the Hercules loan agreement. That payoff removed a secured term loan that had a floating rate structure between 8.95% and 9.45% and a maturity schedule into 2030.
The financing traded complexity for flexibility: high-cost secured debt was repaid and launch and pipeline needs were funded before the PDUFA, at the cost of new shares and a convertible-note overhang whose dilution depends on the share price and settlement choices.
June 30 common shares were 113,238,218; preferred stock converts into a further 12,110,874, giving 125,349,092 common-equivalent shares. This excludes potential note conversion, options and subsequent changes. At the October 1, 2026 close of $18.99 the two bases imply approximately $2.150 billion and $2.380 billion respectively.
June cash and investments $981.530M comprise cash/equivalents $164.986M and marketable securities $816.544M. Q2 revenue $0.284M was license/collaboration revenue, not Lumvoa product sales. First-half operating cash outflow was $224.978M. In the 10-Q, management states that existing cash and securities will fund planned operations for at least twelve months and, on current plans, to break even, defined as the point where anticipated revenues fund anticipated operating expenses; it also warns that more capital may be needed earlier.
Final May financing included $250M note principal and $143.750M gross common-stock proceeds. The notes carry 1.75%, mature May 15, 2032 and initially convert at 40.568 shares per $1,000 (about $24.65). Initial all-stock conversion would represent 10.142M shares, but settlement terms and adjustments matter. June carrying value $242.159M is not principal.
SEC 10-QUSD millions. Total $981.530M; excludes the $75M receivable.
Source: Viridian · SEC Q2 2026
USD millions. Operating expenses $126.552M; not cash flow.
Source: Viridian · SEC Q2 2026
The manufacturing agreement with WuXi Biologics deserves explicit placement in the hub because VRDN has moved into launch mode. On May 24, 2026, Viridian entered into a commercial manufacturing services agreement under which WuXi Biologics will manufacture and supply anticipated long-term commercial requirements of veligrotug drug substance and drug product. The agreement is non-exclusive, meaning Viridian can also procure product from alternate manufacturers.
For a newly commercial biologic, supply, quality systems, validated processes and distribution are part of the launch. Viridian’s Q1 update stated that commercial supply, manufacturing, distribution and supply chain infrastructure were established and ready for launch; the WuXi agreement is the formal filing behind that message.
Launch readiness is necessary, but it is not launch success: that depends on physician awareness, payer access, patient identification, reimbursement support, infusion logistics and competition from an entrenched Tepezza ecosystem.
DRI paid $55 million upfront in October 2025. The $75 million approval milestone was a June 30 receivable and was collected in July; it was not part of the $981.530 million June cash/investments. The company failed to meet certain REVEAL milestones and is no longer eligible for the $25 million and $15 million payments. The headline facility amount is not undrawn cash.
Remaining provisions include $50 million conditional on elegrobart approval, an optional $50 million tied to a $1.1 billion sales threshold within contractual timing, and $30 million subject to further agreement. None is unconditional liquidity.
Marginal U.S. sales tiers carry 7.5% royalty up to $600 million, 0.8% from $600–900 million, 0.25% from $900 million–$2 billion, and none above $2 billion. The first rate may increase if elegrobart misses a contractual approval deadline. These are tiers, not a flat rate on all sales.
June 30 royalty liability $113.642 million and derivative liability $13.690 million are distinct accounting balances. The estimated 27.4% effective interest rate reflects modeled future cash flows; it is not a cash coupon.
July 1, 2026 Form 4s report option awards covering 32,341 shares each to Arlene Morris, Tomas Kiselak, Sarah Gheuens, Jennifer K. Moses, Jeffrey Robert Ajer and Christopher W. Cain. Each has an $18.48 exercise price and expires July 1, 2036; vesting is at the earlier of July 1, 2027 or the 2027 annual meeting, subject to service. The $0 acquisition-price entry describes the award, not a zero exercise price or an open-market purchase. SEC insider ownership filing. SEC insider ownership filing. SEC insider ownership filing. SEC insider ownership filing. SEC insider ownership filing. SEC insider ownership filing.
Steve Mahoney is Viridian’s President and Chief Executive Officer and a member of the board. His background is relevant because the next phase is commercial execution, not only clinical development. Before Viridian, he served as CFO and COO at Magenta Therapeutics, was part of the founding team at Kiniksa Pharmaceuticals where he served as President and COO, held commercial leadership roles at Synageva Biopharma, and worked earlier as a commercial attorney at Genzyme.
The management challenge is to avoid letting expectations run ahead of evidence. The launch phase will judge physician adoption, payer access, early revenue and spending discipline, and a commercial-transition biotech can lose credibility quickly if management overpromises.
Insider filings since approval show option activity rather than open-market buying. On August 19, 2026 Chief Legal Officer Jennifer Tousignant exercised 10,000 options at $14.41 and sold 14,212 shares at $24.50, including 718 shares bought through the employee stock purchase plan (Form 4). On August 14 Chief Medical Officer Radhika Tripuraneni exercised 40,000 fully vested options at $13.21 (Form 4).
At the June 2026 annual meeting stockholders elected Class II directors Tomas Kiselak and Jennifer K. Moses to serve until the 2029 annual meeting, ratified KPMG LLP as independent registered public accounting firm for fiscal 2026, approved named executive officer compensation on an advisory basis, and supported an annual advisory vote frequency.
A May 15 Schedule 13G reported Bellevue Group’s 6,726,144 shares, or 6.6%, as of March 31, 2026. The filing was made jointly by Bellevue Group AG and its wholly owned subsidiary Bellevue Asset Management AG, and both report the same single position. It is a dated beneficial-ownership snapshot, not a current October percentage. SEC Schedule 13G filing.
Institutional ownership is an aggregation of filings with different dates and denominators. Finviz reports 119.37% on October 2, 2026: it cannot be charted as an exclusive share of the capital or used to infer a negative retail holding. Analyst coverage is not downside protection.
The official analyst coverage list includes major healthcare and life-science desks such as Citizens JMP, Evercore ISI, Goldman Sachs, H.C. Wainwright, Jefferies, Leerink, LifeSci Capital, Needham, RBC Capital Markets, Stifel, TD Cowen, Truist, UBS, Wedbush, Wells Fargo, William Blair and Wolfe Research. Broad coverage helps visibility but lets expectations reset quickly after every FDA, clinical or competitive update.
Schedule 13G filings give a dated view of the specialist base. Point72 Asset Management reported 5.0% with an event date of August 19, 2026 (13G). Filings made in August for holdings as of June 30 show Paradigm BioCapital at 6.1%, Kynam Capital at 5.7%, State Street at 5.5% and T. Rowe Price at 5.2%, while Deep Track Capital reported 3.25%, below the 5% threshold. Specialist funds can support a biotech thesis, but they can also de-risk quickly when the data/expectation gap changes, as the March REVEAL-1 reaction showed.
StockTwits, as of October 2, 2026: sentiment score 68/100, labeled bullish, up from 42/100 bearish on September 5; 9,967 watchers. These normalized scores are not percentages of investors and reflect non-professional traders. Posts on September 5 included acquisition rumors and manipulation claims, none verified. A September 1 post pointed to the UHC bulletin: the policy that took effect on October 1 sets criteria rather than blanket coverage.
The core competitor is Amgen’s Tepezza, which validated the TED biologic market. The disease category, physician call point and reimbursement pathway already exist, but so do an incumbent’s brand familiarity, payer relationships and incentive to defend the market.
Lumvoa’s angle is the shorter IV course; elegrobart’s is potential subcutaneous self-administration. Neither wins automatically if payers prefer the incumbent, physicians are cautious or safety language narrows enthusiasm.
Amgen’s lifecycle strategy is no longer hypothetical. On April 6, 2026 Amgen reported positive topline Phase 3 results for subcutaneous Tepezza delivered by an on-body injector every two weeks for 12 injections: a week 24 proptosis responder rate of 76.7% versus 19.6% for placebo, and mean proptosis reduction of 3.17 mm versus 0.80 mm (Amgen release). The trial allowed patients with baseline hearing impairment. Cross-trial comparisons with REVEAL are not valid as head-to-head evidence, but the result narrows the convenience gap elegrobart was meant to open.
A second subcutaneous challenger works through a different mechanism. Genentech’s Enspryng (satralizumab), an IL-6 receptor antibody already marketed in another indication, is under Priority Review in TED with an FDA decision expected by October 15, 2026. SatraGO-2 met its proptosis endpoint, 53% versus 23% at week 24, while SatraGO-1 did not reach significance, 49% versus 31% (Genentech release). Viridian positions elegrobart as potentially the first low-volume subcutaneous autoinjector in TED; an approved at-home rival would make that claim narrower in practice.
Payers are now part of the competitive map. UnitedHealthcare’s commercial policy effective October 1 places Lumvoa and Tepezza under one set of criteria, requires the prescriber to be an endocrinologist or ophthalmologist, does not allow switching between the two drugs after treatment, and caps lifetime doses at five for Lumvoa and eight for Tepezza (UHC bulletin). The key question is not whether Viridian can produce positive clinical data; it already has. It is whether those data and dosing advantages survive commercial comparison against larger companies with established products.
By October 15, 2026: FDA decision expected on Genentech’s Enspryng in TED, a competitor event. Third-quarter results: date not announced as of October 4; the report will be the first to include a full quarter of Lumvoa sales. Europe: the veligrotug MAA submitted in January 2026 is under EMA review, with no disclosed decision date.
Company targets: VRDN-008 healthy-volunteer Phase 1 data in H2 2026; TSHR IND in Q4 2026; VRDN-006 development plans during 2026; elegrobart BLA in Q1 2027. These windows are guidance, not fixed readout or approval dates. The June 29 launch call, the September 8 Wells Fargo presentation and the October 1 UnitedHealthcare policy date belong to the historical timeline.
Viridian Therapeutics has moved from a pending PDUFA to an approved product launch. Lumvoa is FDA approved for TED regardless of disease activity or duration, carries a five-infusion 12-week dosing message and is the company’s first commercial product. The approval removed the obvious binary risk and exposed a harder question: can the company execute commercially against Tepezza, payer criteria such as UnitedHealthcare’s five-dose cap, and possible new subcutaneous rivals?
The cleanest way to follow VRDN is to separate four layers: the label, broad but with hearing, hyperglycemia, IBD and infusion-reaction monitoring; the commercial launch, where payer access and patient starts decide the revenue line; the portfolio, where elegrobart depends on a Q1 2027 filing and an FDA decision; and the balance sheet, strong in cash but carrying burn, convertibles, royalties and preferred-share dilution.
The conclusion is more constructive than before approval, but not blindly bullish. The third-quarter report, the first with a full quarter of Lumvoa sales, and the FDA decision on Enspryng due by October 15 are the next pieces of evidence the market will weigh.
Track biotech catalysts: Merlintrader keeps a dedicated free catalyst calendar for FDA, PDUFA, clinical and biotech event tracking.
Marketstack supplies the October 1, 2026 closing price. Finviz ownership and float fields are as of October 2, 2026 and may reflect older underlying dates; short interest is the FINRA figure for the September 15, 2026 settlement date published by Nasdaq. Financial amounts come from the June 30 SEC 10-Q; dated company releases, the approved label and the payer bulletin are linked above. No analyst target is adopted.
Yes. The FDA approved Lumvoa (veligrotug-vvze) on June 26, 2026, ahead of the June 30 PDUFA date, for thyroid eye disease regardless of activity or duration: five IV infusions every three weeks. First doses were given in July.
Viridian guides to a BLA for subcutaneous elegrobart in the first quarter of 2027, restated on August 6, 2026, after REVEAL-1 and REVEAL-2 met their primary endpoints. A filing is not an approval.
$981.5 million of cash, equivalents and marketable securities at June 30, 2026, excluding a $75 million DRI receivable collected in July. The company expects cash plus anticipated product revenue to fund its plans through profitability.
Lumvoa has been on UnitedHealthcare’s Review at Launch list since July 15, 2026, so some members may not yet be eligible. Criteria effective October 1, 2026 include moderate-to-severe TED, a specialist prescriber, no prior Tepezza and at most five lifetime doses.
Amgen’s IV Tepezza is the incumbent, with positive Phase 3 data for a subcutaneous version reported on April 6, 2026. Genentech’s subcutaneous Enspryng has a TED decision expected by October 15, 2026.
113,238,218 common shares at June 30, 2026, or 125,349,092 including preferred conversions; the 2032 convertible notes represent about 10.1 million more at the initial rate.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $VRDN or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Viridian is a commercial-stage biotechnology company. Lumvoa uptake, payer access, operating costs, safety monitoring and reliable supply will influence launch economics. Pipeline trials and regulatory submissions remain uncertain, and financing needs depend on spending, revenue and contractual proceeds. Loss of capital remains possible. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
